AbbVie's Telisotuzumab Adizutecan Receives Two FDA Breakthrough Therapy Designations for Colorectal and Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) to AbbVie's investigational antibody-drug conjugate (ADC), telisotuzumab adizutecan (Temab-A), for the treatment of colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). These designations aim to expedite the development and review of Temab-A, which targets the c-Met protein and is being investigated in advanced solid tumors.